Wall Street Journal, February 20, 2017
Christopher Alessi


Read the Full Article

This article is behind a paywall. Harvard affiliates can access it via Hollis+.

FRANKFURT—Investors in Bayer AG have taken heart from President Donald Trump’s apparent support for the German pharmaceuticals and chemicals firm’s planned $57 billion takeover of U.S. seed giant Monsanto Co. and are cautiously optimistic the deal will pass regulatory muster. [...]

biotechnology food genetics international market pharmaceuticals regulation